GTHP · Guided Therapeutics Inc
$0.19
+0.03 (+18.75%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The factors below raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$18.34M
Shares
96.54M
Volume · Oct 20
154.21K
Avg daily vol (3M)
36.07K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.19
Open$0.16
Day$0.16–0.20
52W close$0.16–0.54
Avg vol 30d53K
Short int4K · 0.0% float · 1.0d
Short vol82%
DataJan 2021–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$650,000
Trailing 12 months
Net income (TTM)
−$3.06M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-303.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$41,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.4%
Year over year · more shares
Price change (1Y)
-24.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−20%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−34%
trailing
YTD return
−65%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -45.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
28
low risk · 0–100
Fundamentals
Revenue growth
+10857%
Y/Y
Gross margin
74%
expanding
EPS growth
+20%
Y/Y
Free cash flow
$-1.1M
Balance sheet
$621.0K
net cash
Quant / Vol
risk profile
Volatility
196%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
16.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -45.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 8%
Range high $1
vs 200-day avg -30%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTHP
this stock
Guided Therapeutics Inc
|
$18.34M | -64.8% | +10857.1% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$121.04B | -1.5% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 0.0%
- Net QoQ
- -1 sh
- Top holder
- Steward Partners Investme…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTHP | +5.6% | -24.0% | -34.0% | -23.4% | -64.8% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +6.7% | -23.4% | -42.1% | -24.2% | -77.6% |